Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

Core Insights - Sanofi reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, exceeding the Zacks Consensus Estimate of 90 cents per share, with earnings of €1.79 per share rising 17.0% on a reported basis and 15.7% on a constant currency rate [1][20] - Net sales increased by 10.8% on a reported basis to $10.42 billion (€9.9 billion), but fell short of the Zacks Consensus Estimate of $10.63 billion, with a 9.7% rise on a constant currency basis [2][19] Financial Performance - Dupixent sales reached €3.48 billion, up 20.3% year over year, driven by strong prescription trends across all geographies, surpassing model estimates [4] - Sales of Altuviiio, a new rare blood disorder drug, were €251 million, showing growth from €230 million in the previous quarter, with over 87% of sales in the U.S. [8] - Total vaccine sales increased by 11.4% to €1.33 billion, driven by favorable sales of Beyfortus [15] Product Performance - Dupixent sales in the U.S. rose 18.4%, with significant growth in Europe (23.5%) and the Rest of the World (26.5%) [5][6] - Sales of Nexviazyme/Nexviadzyme were €195 million, up 26.3% year over year, while Myozyme sales declined 29.8% to €135 million due to patient switches [9][10] - In neurology, Aubagio sales fell 37.3% to €65 million due to generic competition, while Sarclisa sales rose 26.4% to €136 million [13] Future Outlook - Sanofi maintained its 2025 guidance, expecting sales to rise by a mid-to-high single-digit percentage at constant currency and earnings to rebound strongly with low double-digit percentage growth [18] - The company anticipates three potential new drug launches this year, including Qfitlia/fitusiran, which was approved for treating hemophilia A and B [21] - Sanofi is on track to separate its Consumer Healthcare unit, creating a publicly listed entity called Opella [22]